A carregar...
Severe Esophagitis and Gastritis from Nivolumab Therapy
Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, howev...
Na minha lista:
| Publicado no: | ACG Case Rep J |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American College of Gastroenterology
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5404341/ https://ncbi.nlm.nih.gov/pubmed/28459081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14309/crj.2017.57 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|